CRISPR - InVivo Biosystems

Let’s Fail Faster: Why Scientific Failures Should be Accepted as Progress

CRISPR, Drug Discovery / By Alexandra Narin / June 9, 2021 June 11, 2021

In the scientific community there is an emphasis on positive results: getting published, having a drug be approved, etc. However, crucial learning happens when experiments don’t work – in fact, these “failures” may be some of the most important learning experiences. In this article we discuss the need to shift the focus from failing less, to failing faster and some of the resources available to researchers so they can expedite their own work.

Validating Expression of Humanizations – What We’ve Done so Far

In an effort to create better research models for epilepsy, we’ve been working on a grant-funded project to humanize numerous C. elegans genes. Learn more about our progress and our findings in this blog.

So What is Humanization?

CRISPR, Disease Modeling / By Alexandra Narin / May 24, 2021 May 24, 2021

Humanized animal models are becoming more widely used as new gene editing techniques become available and there is a push for a more personalized approach to medicine, but what exactly is humanization? In this article we discuss the history, the types of humanized models, and how they can be applied to your research.

Problem Solved: Using a new technique to solve a problem

CRISPR, View from the Bench / By Jenn Lawson / May 17, 2021 June 3, 2021

Two main lessons learned: 1. stay current with a broad variety of literature and 2. always be willing to try new methods

Check it before you wreck it

CRISPR, View from the Bench / By Stelian Pop / May 3, 2021 May 3, 2021

Mistakes can happen, various design issues can be overlooked, or maybe just a less than optimal design was used, so how do we at InVivo Biosystems minimize such events?

The Next Generation of Animal Models: Humanized Models

CRISPR, Disease Modeling / By Alexandra Narin / April 27, 2021 April 30, 2021

New ‘humanized models’ have the potential to revolutionize the study of clinical diseases, creating models with higher validity than more traditional models. This in turn has the power to expedite getting results from the bench to the bedside. In this article we will discuss the current state of animal models and the future that humanized models make possible; as an example, we will specifically focus on the models of Alzheimer’s Disease (AD).